CONTACT A REP
Patients HCP
This site is for US Health Care Professionals only.

About GEP-NET Patients

Role of SSTR

GEP-NETs may vary but the majority share an overexpression of SSTR1

Almost 90% of GEP-NETs overexpress SSTR2.

High expression of somatostatin receptors (SSTRs) modulates tumor proliferation and hormone secretion1
 

Consider a holistic, individual evaluation of tumor characteristics when selecting the appropriate therapy for patients2,3:

Icon of a magnifying glass over the shape of a person

Use SSTR imaging to confirm whether their advanced disease may benefit from SSTR-directed therapies

Icon of two tumors

Evaluate primary tumor site, tumor grade, overall tumor burden, and comorbidities

How LUTATHERA works: Delivering tumor-destroying radiation to SSTR+ GEP-NETs4-6
SSA targets SSTR+ GEP-NET cells to control tumor symptoms and growth. LUTATHERA also acts against and destroys SSTR+ GEP-NET cells.

Based on preclinical models. LUTATHERA delivers radiation that causes damage to the SSTR+ cells as well as neighboring, healthy cells.

GEP-NETs, gastroenteropancreatic neuroendocrine tumors; SSA, somatostatin analogue; SSTR+, somatostatin receptor-positive.

References: 1. Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42(3):220-225. 2. Eads JR, Halfdanarson TR, Asmis T, et al. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023;30(8):e220206. 3. Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41(32):5049-5067. 4. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 5. Somatuline. Prescribing information. Ipsen Biopharmaceuticals, Inc. 6. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663.